Official UK procurement notice
NHS Generic Pharmaceuticals - Lenalidomide, Pomalidomide & Thalidomide
Authority: NHS England (Central government)
What is being bought3 lots · detail below
Published requirement descriptionNHS National Framework for Lenalidomide, Pomalidomide & Thalidomide.
Offer reference number: CM/PHG/24/5716
Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) for a period or periods up to a total of 48 months.
Periods of call-offs under the framework agreement:
CM/PHG/24/5716/01– NHS National Framework for Lenalidomide, Pomalidomide & Thalidomide.
CESW: (Midlands and Southwest): 1st June 2026 – 31st May 2028
NWLN: (Northwest and London North): 1st June 2026 – 31st May 2028
LSNE: (London South and Northeast): 1st June 2026 – 31st May 2028
CPV: Pharmaceutical products
How this framework works
From the published notice- Type
- Open framework
- Call-offs
- every call-off is a further competition among the appointed suppliers
- Bids received
- 12 bids received · 11 suppliers appointed
- Framework period
- 2 yrs · up to 4 yrs from 1 Jun 2026
- Buyer regions
- UKC, UKD, UKE, UKF, UKG, UKH, UKI, UKJ, UKK
Who may buy through it
See Purchasing Points list in tender document set
Published description of the framework
Please refer to the ITO Documents for the Operation Description
Lots and requirements (3)Procurement structure
3 lots · all with a published valueEvery one of these 3 lots carries the same published figure, £1: it is the framework's maximum for the whole notice, not each lot's own budget, and no share per lot is published. The cards below say ceiling above rather than repeat it.
Lot #1LenalidomideAwardedRenewalceiling above
Lenalidomide
CESW: (Midlands and Southwest): 1st June 2026 – 31st May 2028
NWLN: (Northwest and London North): 1st June 2026 – 31st May 2028
LSNE: (London South and Northeast): 1st June 2026 – 31st May 2028
Lot #2PomalidomideRenewalceiling above
Pomalidomide
CESW: (Midlands and Southwest): 1st June 2026 – 31st May 2028
NWLN: (Northwest and London North): 1st June 2026 – 31st May 2028
LSNE: (London South and Northeast): 1st June 2026 – 31st May 2028
Lot #3ThalidomideRenewalceiling above
Thalidomide
CESW: (Midlands and Southwest): 1st June 2026 – 31st May 2028
NWLN: (Northwest and London North): 1st June 2026 – 31st May 2028
LSNE: (London South and Northeast): 1st June 2026 – 31st May 2028
What it takes to wini
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
Evaluation split and conditions of participation as published; the tender pack may add morei
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
- “NHS Generic Pharmaceuticals - Lenalidomide, Pomalidomide & Thalidomide” is a framework: the contest is a place on its panel, not a single contract: each call-off is a further competition, so the pricing contest starts after appointment.
Procedure terms & legal framework
From the official record- Procedure method
- Open procedure
- Legal basis
- UKPGA · 2023/54 Procurement Act 2023
- Procurement category
- Goods
- Notice status
- Awarded
- Procurement threshold
- Above threshold (FTS publication)
- Regulatory regime
- Standard
- Commercial structure
- Framework agreement
- Who may use the vehicle
- See Purchasing Points list in tender document set
- Competition type
- Competitive procedure
- GPA / WTO covered
- Yes (GPA)
- Recurring procurement
- Unspecified in notice
- First published
- 21 May 2025, 18:39 BST
- Last source update
- 28 May 2026, 16:58 BST
- Award evaluation window
- Submission end – 16 Mar 2026
- Authority reference
CM/PHG/24/5716- FTS notice number
2026/S 000-010573- Latest notice
- Contract details notice (UK7)
- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-051c39Find a Tender
How it was run
Official notice- Appointment period ends
- 9 Mar 2026, 13:00 GMT
- Clarification deadline
- 2 Mar 2026, 17:00 GMT
- Submission channel
- Official e-sourcing portal
- Electronic submission
- Allowed
- Accepted languages
- en
The procurement documents are
available for unrestricted and full direct
access, free of charge at health-family.force.com/s/Welcome ↗
Additional information may be obtained
from the abovementioned address.
Tenders must be submitted to the
above mentioned address.
Timeline
21 May 2025 → 1 Jun 2026 · 11 dates- Planning notice published21 May 2025, 18:39 BST
- Market engagement258 days ago30 Jan 2026, 23:59 GMT
NHS England is advising suppliers of an upcoming tender for the NHS Generics Pharmaceuticals – Lenalidomide, Pomalidomide & Thalidomide to commence on 1st June 2026 for 24 months with options to extend for a maximum total contract period of 48 months. This procurement will consist Lenalidomide, Pomalidomide and Thalidomide products across all regions of the country. The purpose of this notice is to inform existing and potential new suppliers of this procurement. Useful information for suppliers can be found here www.england.nhs.uk/medicines-2/medicine… ↗ . Specific information regarding the products included in this procurement will be provided in the ITO which will be issued shortly.
- Next notice expected255 days ago2 Feb 2026, 23:59 GMT
- Tender notice published253 days ago5 Feb 2026, 15:03 GMT
- Clarification questions by227 days ago2 Mar 2026, 17:00 GMT
- Admission / appointment period ends221 days ago · period end, not a bid countdown9 Mar 2026, 13:00 GMT
- Award decision expected by213 days ago16 Mar 2026, 23:59 GMT
- Assessment summaries sent204 days ago26 Mar 2026
- Standstill ends190 days ago8 Apr 2026, 23:59 BST
- Latest notice published141 days ago28 May 2026, 16:58 BST
- Contract starts137 days ago1 Jun 2026, 00:00 BST
Notice history
12 events · 5 releases on Find a Tender · since 21 May 2025- Pipeline notice published21 May 2025, 18:39 BSTUK1
- Preliminary market engagement notice published23 Jan 2026, 10:29 GMTUK2
- Published value updated to £196,203,12023 Jan 2026, 10:29 GMTwas £38,115,172
- Tender notice published5 Feb 2026, 15:03 GMTUK4
- Published value updated to £33,981,9285 Feb 2026, 15:03 GMTwas £196,203,120
- Status changed to active5 Feb 2026, 15:03 GMT
- Procurement method changed5 Feb 2026, 15:03 GMT
- Deadline published: 9 Mar 2026, 13:00 GMT5 Feb 2026, 15:03 GMT
- Contract award notice published26 Mar 2026, 12:18 GMTUK6
- Status changed to complete26 Mar 2026, 12:18 GMT
- Contract signature expected17 Apr 2026, 23:59 BSTscheduled
- Contract details notice published28 May 2026, 16:58 BSTUK7
Routine re-releases (5)
- 2026-01: 1 release · 23 Jan 2026
- 2025-05: 1 release · 21 May 2025
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast| Awarded to | Value | Date | Status |
|---|---|---|---|
| Lot 1 · Lenalidomide1 award | |||
| ACCORD-UK LTD, Amarox LimitedSME, Milpharm Limited, Ranbaxy (UK) LtdSME, Reig Jofre UKSME, Thornton and Ross Ltd +5 moreNHS National Generics Framework for Lenalidomide, Pomalidomide and Thalidomide1 Jun 2026 – 31 May 2028 · up to 31 May 2030Extensions: Option or options to extend (at the authority’s discretion) for a period or periods up to a total of 24 months. · Options: Option or options to extend (at the authority’s discretion) for a period or periods up to a total of 24 months. | £19,595,208 | 24 Mar 2026 | Awarded |
Contracts
NHS National Generics Framework for Lenalidomide, Pomalidomide and Thalidomide · ACCORD-UK LTD, Amarox LimitedSME, Milpharm Limited, Ranbaxy (UK) LtdSME, Reig Jofre UKSME, Thornton and Ross Ltd +5 more
- Signed
- 13 Apr 2026
- Value
- £19,595,208
- Period
- 1 Jun 2026 – 31 May 2028 · up to 31 May 2030 with extensions
- Status
- active
- Extensions
- Option or options to extend (at the authority’s discretion) for a period or periods up to a total of 24 months.
- Options
- Option or options to extend (at the authority’s discretion) for a period or periods up to a total of 24 months.
Bid statistics published by the authority
| Lot | Bids | SME | VCSE | Valid bid range |
|---|---|---|---|---|
| 1 · Lenalidomide | 12final-stage tenders | 6 | 0 | — |
Who bid
- wonACCORD-UK Ltd · South West England · 1
- wonAmarox LimitedSME · Greater London · 1
- did not winLipomed AGSME · 1
- wonMilpharm Ltd · Greater London · 1
- wonThornton and Ross Ltd · Yorkshire and the Humber · 1
- did not winWockhardt UK LimitedSME · Wales (Cymru) · 1
- wonReig Jofre UK limitedSME · South West England · 1
- wonSUN PHARMA UK LIMITEDSME · Greater London · 1
- did not winTeva UK Limited · Yorkshire and the Humber · 1
- wonViatris UK Healthcare Limited · East of England · 1
- wonZentiva Pharma UK Ltd · South East England · 1
- did not winGrindeks Kalceks UK LtdSME · East of England · 1
Bidders as named on the Procurement Act 2023 award notice. “Won” means the bidder holds an award on this notice.
Contracting authority & participating public bodies
Framework contractors & participating bidders
12 commercial parties on the notice · 11 awarded- ACCORD-UK LtdFramework contractor
- Amarox LimitedFramework contractor
- Grindeks Kalceks UK LtdBidder / tenderer
- Lipomed AGFramework contractor
- Milpharm LtdFramework contractor
- Reig Jofre UK limitedFramework contractor
- SUN PHARMA UK LIMITEDFramework contractor
- Teva UK LimitedFramework contractor
- Thornton and Ross LtdFramework contractor
- Viatris UK Healthcare LimitedFramework contractor
Show 2 more suppliers
- Wockhardt UK LimitedFramework contractor
- Zentiva Pharma UK LtdFramework contractor
Official documents & specifications (8)
Official links; attachments are not copiedTender pack and attachments
Notices published for this procedure
- Contract details notice Contract details notice on Find a Tender
- Contract award notice Contract award notice on Find a Tender
- Tender notice Tender notice on Find a Tender
- Preliminary market engagement notice Preliminary market engagement notice on Find a Tender
- Pipeline notice Pipeline notice on Find a Tender